糖肽类抗菌药物利用评价标准的建立与应用分析
|
摘要
目的建立糖苷类抗菌药物(万古霉素和替考拉宁)的药物利用评价标准,并评价糖肽类抗菌药物临床用药情况。方法以药品说明书为基础,参照相关规范和专家共识,建立万古霉素和替考拉宁药物利用评价标准;采用回顾性研究方法,对2017年1月—6月274例使用万古霉素和替考拉宁的病例进行合理性评价。结果糖肽类抗菌药物治疗有效率为75.91%,用药指征符合率为92.70%,剂量正确率为98.18%,用法正确率为91.24%,疗程合理率为79.93%,联合用药合理率为72.26%。结论建立的万古霉素和替考拉宁药物利用评价标准可用于规范糖肽类抗菌药物的使用,该院万古霉素和替考拉宁的使用基本合理。
OBJECTIVE To establish drug use evaluation(DUE) criteria for vancomycin and teicoplanin, to evaluate clinical use of glycopeptides antibiotics in a hospital of the three levels of first class. METHODS Based on vancomycin and teicoplanin instructions, referring to related specifications and literatures, DUE criteria for vancomycin and teicoplanin were established. The utilization of glycopeptides antibiotics in 274 inpatients of the hospital during Jan 2017-Jun 2017 was evaluated in retrospective study. RESULTS The treatment effective rate of glycopeptides antibiotics was 75.91%, the coincidence rate of medication indication was 92.70%, the rate of accuracy dosage was 98.18%, the rate of accuracy administration was 91.24%, the rate of rational duration of treatment was 79.93%, the rate of rational combined drug was 72.26%. CONCLUSION Established DUE criteria of vancomycin and teicoplanin can standardize the clinical utilization of glycopeptides antibiotics, clinical use of vancomycin and teicoplanin is basically reasonable in this hospital.
OBJECTIVE To establish drug use evaluation(DUE) criteria for vancomycin and teicoplanin, to evaluate clinical use of glycopeptides antibiotics in a hospital of the three levels of first class. METHODS Based on vancomycin and teicoplanin instructions, referring to related specifications and literatures, DUE criteria for vancomycin and teicoplanin were established. The utilization of glycopeptides antibiotics in 274 inpatients of the hospital during Jan 2017-Jun 2017 was evaluated in retrospective study. RESULTS The treatment effective rate of glycopeptides antibiotics was 75.91%, the coincidence rate of medication indication was 92.70%, the rate of accuracy dosage was 98.18%, the rate of accuracy administration was 91.24%, the rate of rational duration of treatment was 79.93%, the rate of rational combined drug was 72.26%. CONCLUSION Established DUE criteria of vancomycin and teicoplanin can standardize the clinical utilization of glycopeptides antibiotics, clinical use of vancomycin and teicoplanin is basically reasonable in this hospital.
引文
[1]陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:86.
[2]国家卫生计生委,国家中医药管理局,总后勤部卫生部.抗菌药物临床应用指导原则:2015版[S].2015.
[3]国家卫生计生委.2013年全国抗菌药物临床应用专项整治活动方案[S].2013.
[4]佚名.万古霉素临床应用中国专家共识:2011版[J].中国新药与临床杂志,2011,30(8):561-573.
[5]佚名.替考拉宁临床应用剂量专家共识[J].中国结核和呼吸杂志,2016,39(7):500-508.
[6]LI Y,LV Y,XUE F,et al.Antimicrobial susceptibility surveillance of gram-positive bacterial from Ministry of Health National Antimicrobial Resistant Investigation Net(Mohnarin)2011-2012[J].Chin J Clin Pharmacol(中国临床药理学杂志),2014,30(3):251-259.
[7]WANG F Q,YANG F.Research progress of vancomycin and linezolid on the treatment of central nervous system infections in children[J].Chin J Mod Appl Pharm(中国现代应用药学),2017,34(2):301-304.
[8]LIN Z,CHEN M F,CUI K,et al.Population pharmacokinetics of vancomycin in Chinese adult infection patients[J].Chin JMod Appl Pharm(中国现代应用药学),2017,34(1):101-106.
[9]TAO L N,QU X Y,ZHANG S X,et al.Analysis of 720 patients of clinical use of vancomycin in our hospital from2013 to 2014[J].China Pharm(中国药业),2017,28(12):1647-1651.
[10]ZHAO M,LIANG L,JI L W,et al.Analysis on medication rationality of teicoplanin in clinical practices[J].Clin Med J(临床药物治疗杂志),2016,14(3):57-60.
[11]LIANG B B,NI W T,WANG J.et.al.Effectiveness and safety of teicoplanin versus vancomycin for the treatment of gram-positive bacterial infections:Meta analysis of randomised controlled trials[J].Chin J Clin Pharmacol(中国临床药理学杂志),2017,33(2):176-180.
[2]国家卫生计生委,国家中医药管理局,总后勤部卫生部.抗菌药物临床应用指导原则:2015版[S].2015.
[3]国家卫生计生委.2013年全国抗菌药物临床应用专项整治活动方案[S].2013.
[4]佚名.万古霉素临床应用中国专家共识:2011版[J].中国新药与临床杂志,2011,30(8):561-573.
[5]佚名.替考拉宁临床应用剂量专家共识[J].中国结核和呼吸杂志,2016,39(7):500-508.
[6]LI Y,LV Y,XUE F,et al.Antimicrobial susceptibility surveillance of gram-positive bacterial from Ministry of Health National Antimicrobial Resistant Investigation Net(Mohnarin)2011-2012[J].Chin J Clin Pharmacol(中国临床药理学杂志),2014,30(3):251-259.
[7]WANG F Q,YANG F.Research progress of vancomycin and linezolid on the treatment of central nervous system infections in children[J].Chin J Mod Appl Pharm(中国现代应用药学),2017,34(2):301-304.
[8]LIN Z,CHEN M F,CUI K,et al.Population pharmacokinetics of vancomycin in Chinese adult infection patients[J].Chin JMod Appl Pharm(中国现代应用药学),2017,34(1):101-106.
[9]TAO L N,QU X Y,ZHANG S X,et al.Analysis of 720 patients of clinical use of vancomycin in our hospital from2013 to 2014[J].China Pharm(中国药业),2017,28(12):1647-1651.
[10]ZHAO M,LIANG L,JI L W,et al.Analysis on medication rationality of teicoplanin in clinical practices[J].Clin Med J(临床药物治疗杂志),2016,14(3):57-60.
[11]LIANG B B,NI W T,WANG J.et.al.Effectiveness and safety of teicoplanin versus vancomycin for the treatment of gram-positive bacterial infections:Meta analysis of randomised controlled trials[J].Chin J Clin Pharmacol(中国临床药理学杂志),2017,33(2):176-180.